BioWorld

Aug. 5, 2004

Avera's Venture Round Gets $48M For Neuroscience Bid

Although going about the typical process for a biotechnology firm backward, Avera Pharmaceuticals Inc. proved it can make the model work, raising $48 million in a Series C round of venture capital funding. (BioWorld Today) Read More

Ceregene Raises $32M, Sends CNS Therapies Toward Clinic

Kalypsys Plans To Advance Pipeline With $29M Series B

Alnylam Acquires Rights To VEGF Patents From Hybridon

Inex Loses GSK As Partner For Liposomal Cancer Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...